Drug Development Pipeline
Fosfomycin/Tobramycin Inhalation Solution (FTI)
Fosfomycin/tobramycin inhalation solution (FTI) is a combination antibiotic consisting of fosfomycin and tobramycin. FTI has shown increased effectiveness against bacteria compared to fosfomycin or tobramycin alone.
A phase 2b study to test the safety and effectiveness of FTI is planned.
This program is sponsored by CURx Pharmaceuticals. It is being conducted within the Therapeutics Development Network.
Recent Fosfomycin/Tobramycin Inhalation Solution (FTI) Studies
Completed with Results
Sign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Explore clinical trials
Be a part of the movement transforming the future of cystic fibrosis treatment.Learn More